Cereno Scientific sets study timeline of upcoming Phase II study with CS1 in rare disease PAH to start September 2021
Cereno Scientific today announced that the timelines for the upcoming clinical Phase II with drug candidate CS1 has been set following the signing of the final agreements with clinical research organization Worldwide Clinical Trials. The preparatory work together with Worldwide has proceeded since a letter of intent (LOI) was signed earlier this year, resulting in a study timeline for the Phase II study with CS1 in PAH anchored with relevant parties. If the study timeline is followed according to plan, the first patient will start in September 2021 with study results expected in H2 2022.“